A Phase 3 interventional study of Vonoprazan and Lansoprazole in Erosive Esophagitis, sponsored by Phathom Pharmaceuticals, Inc.. Completed at 157 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-29.
Sponsored by Phathom Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing vonoprazan in Esophagitis — 1 open to participants now, 1 under way, none of them phase 3. vonoprazan · Esophagitis.
Among the 10 studies testing vonoprazan in Esophagitis, this one has the largest enrollment, is the only one that started in 2019, is one of 7 in phase 3, and was the 8th registered.
123 studies on the registry are indexed under Esophagitis; 15 are open to participants now.
Browse Esophagitis studies →1 of the 10 studies testing vonoprazan in Esophagitis is open now, in 1 country. Recruiting first, the newest first:
Indonesia University · Sites in Indonesia
Ages 18+
By country, each count listing its studies:
vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →
Of the 10 Esophagitis studies recruiting now, 6 (60%) set no upper age limit and 4 (40%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2019.
This study's enrollment of 1,027 is above the median of 96 across 99 interventional studies indexed under Esophagitis.
Median enrollment 357 across the 10 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 4 most frequent:
Phathom Pharmaceuticals, Inc. is the lead sponsor of 15 studies on the registry; 2 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 11 (100%) have results posted.
Phathom Pharmaceuticals, Inc. has 1 study filed under Esophagitis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing vonoprazan in Esophagitis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of vonoprazan compared to lansoprazole in participants with erosive esophagitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The participant has any of the following abnormal laboratory test values at the start of the Screening Period:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive oral vonoprazan 20 mg once per day (QD) for a maximum of 8 weeks.
Drug: Vonoprazan
Participants will receive oral lansoprazole 30 mg once per day (QD) for a maximum of 8 weeks.
Drug: Lansoprazole
Participants will receive oral vonoprazan 10 mg once per day (QD) for a maximum of 24 weeks.
Drug: Vonoprazan
Participants will receive oral vonoprazan 20 mg once per day (QD) for a maximum of 24 weeks.
Drug: Vonoprazan
Participants will receive oral lansoprazole 15 mg once per day (QD) for a maximum of 24 weeks.
Drug: Lansoprazole
Over-encapsulated tablet administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.
Over-encapsulated capsule administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.
Healing Phase: Percentage of Participants Who Had Complete Healing of EE by Week 8
A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy.
Time frame: Week 8
Maintenance Phase: Percentage of Participants Who Maintained Complete Healing of EE at Week 24
A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy.
Time frame: Week 24
Healing Phase: Percentage of 24-hour Heartburn-free Days
A 24-hour heartburn-free day was defined as a day having no heartburn among all diary entries for that day. The percentage of 24-hour heartburn-free days was calculated using all days with at least 1 evening or morning diary entry during the treatment period of this phase.
Time frame: Day 1 to Week 8
Healing Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Had Complete Healing of EE at Week 2
A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy. LA Classification of Esophagitis Grading Scale: Grade C: One or more mucosal breaks that are continuous between the tops of 2 or more mucosal folds, which involves less than 75% of the circumference. Grade D: One or more mucosal breaks, which involves at least 75% of the circumference.
Time frame: Week 2
Healing Phase: Percentage of Participants With Onset of Sustained Resolution of Heartburn by Day 3
Sustained resolution was defined as at least 7 consecutive days with no daytime or night time heartburn as assessed by the daily diary. A participant was considered to have sustained resolution of heartburn by Day 3 if the first day of the 7 consecutive days without symptoms was on Days 1, 2, or 3.
Time frame: Day 1 to maximum of Day 10 (inclusive of 7 day heartburn assessment)
Healing Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Had Complete Healing of EE by Week 8
A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy. LA Classification of Esophagitis Grading Scale: Grade C: One or more mucosal breaks that are continuous between the tops of 2 or more mucosal folds, which involves less than 75% of the circumference. Grade D: One or more mucosal breaks, which involves at least 75% of the circumference.
Time frame: Week 8
Healing Phase: Percentage of Participants Who Had Complete Healing of EE at Week 2
A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy.
Time frame: Week 2
Maintenance Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Maintained Complete Healing of EE at Week 24
A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy. LA Classification of Esophagitis Grading Scale: Grade C: One or more mucosal breaks that are continuous between the tops of 2 or more mucosal folds, which involves less than 75% of the circumference. Grade D: One or more mucosal breaks, which involves at least 75% of the circumference.
Time frame: Week 24
Maintenance Phase: Percentage of 24-hour Heartburn-free Days
A 24-hour heartburn-free day was defined as a day having no heartburn among all diary entries for that day. The percentage of 24-hour heartburn-free days was calculated using all days with at least 1 evening or morning diary entry during the treatment period of this phase.
Time frame: Day 1 to Week 24
This study was performed at 111 sites in 6 countries (Bulgaria, Czechia, Hungary, Poland, the United Kingdom and the United States) between 28 October 2019 and 24 August 2021. Of the 4,167 participants screened for the study, 1,027 participants with erosive esophagitis (EE) were randomized in the Healing Phase.
| Milestone | Healing Phase: Vonoprazan 20 mg | Healing Phase: Lansoprazole 30 mg | Maintenance Phase: Vonoprazan 10 mg | Maintenance Phase: Vonoprazan 20 mg | Maintenance Phase: Lansoprazole 15 mg |
|---|---|---|---|---|---|
| Started | 514 | 513 | 0 | 0 | 0 |
| Treated with study drug | 514 | 510 | 0 | 0 | 0 |
| Completed | 483 | 481 | 0 | 0 | 0 |
| Not completed | 31 | 32 | 0 | 0 | 0 |
| Withdrew: Pretreatment event, adverse event (ae), or serious ae (sae) | 3 | 7 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 5 | 4 | 0 | 0 | 0 |
| Withdrew: Voluntary withdrawal | 10 | 7 | 0 | 0 | 0 |
| Withdrew: Withdrawal of consent | 5 | 3 | 0 | 0 | 0 |
| Withdrew: Miscellaneous | 8 | 7 | 0 | 0 | 0 |
| Withdrew: Randomized but not treated | 0 | 3 | 0 | 0 | 0 |
| Milestone | Healing Phase: Vonoprazan 20 mg | Healing Phase: Lansoprazole 30 mg | Maintenance Phase: Vonoprazan 10 mg | Maintenance Phase: Vonoprazan 20 mg | Maintenance Phase: Lansoprazole 15 mg |
|---|---|---|---|---|---|
| Started | 0 | 0 | 298 | 298 | 297 |
| Treated with study drug | 0 | 0 | 296 | 296 | 297 |
| Completed | 0 | 0 | 274 | 269 | 269 |
| Not completed | 0 | 0 | 24 | 29 | 28 |
| Withdrew: Pretreatment event, ae, or sae | 0 | 0 | 3 | 5 | 4 |
| Withdrew: Protocol violation | 0 | 0 | 3 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 7 | 8 | 9 |
| Withdrew: Voluntary withdrawal | 0 | 0 | 3 | 6 | 5 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal of consent | 0 | 0 | 5 | 5 | 5 |
| Withdrew: Miscellaneous | 0 | 0 | 1 | 2 | 4 |
| Withdrew: Randomized but not treated | 0 | 0 | 2 | 2 | 0 |
A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy.
| percentage of participants | Healing Phase: Vonoprazan 20 mg | Healing Phase: Lansoprazole 30 mg |
|---|---|---|
| Healing Phase: Percentage of Participants Who Had Complete Healing of EE by Week 8 | 92.9 | 84.6 |
A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy.
| percentage of participants | Maintenance Phase: Vonoprazan 10 mg | Maintenance Phase: Vonoprazan 20 mg | Maintenance Phase: Lansoprazole 15 mg |
|---|---|---|---|
| Maintenance Phase: Percentage of Participants Who Maintained Complete Healing of EE at Week 24 | 79.2 | 80.7 | 72.0 |
A 24-hour heartburn-free day was defined as a day having no heartburn among all diary entries for that day. The percentage of 24-hour heartburn-free days was calculated using all days with at least 1 evening or morning diary entry during the treatment period of this phase.
| percentage of days | Healing Phase: Vonoprazan 20 mg | Healing Phase: Lansoprazole 30 mg |
|---|---|---|
| Healing Phase: Percentage of 24-hour Heartburn-free Days | 66.8 ± 34.60 | 64.1 ± 35.46 |
A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy. LA Classification of Esophagitis Grading Scale: Grade C: One or more mucosal breaks that are continuous between the tops of 2 or more mucosal folds, which involves less than 75% of the circumference. Grade D: One or more mucosal breaks, which involves at least 75% of the circumference.
| percentage of participants | Healing Phase: Vonoprazan 20 mg | Healing Phase: Lansoprazole 30 mg |
|---|---|---|
| Healing Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Had Complete Healing of EE at Week 2 | 70.2 | 52.6 |
Sustained resolution was defined as at least 7 consecutive days with no daytime or night time heartburn as assessed by the daily diary. A participant was considered to have sustained resolution of heartburn by Day 3 if the first day of the 7 consecutive days without symptoms was on Days 1, 2, or 3.
| percentage of participants | Healing Phase: Vonoprazan 20 mg | Healing Phase: Lansoprazole 30 mg |
|---|---|---|
| Healing Phase: Percentage of Participants With Onset of Sustained Resolution of Heartburn by Day 3 | 34.4 | 32.2 |
A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy. LA Classification of Esophagitis Grading Scale: Grade C: One or more mucosal breaks that are continuous between the tops of 2 or more mucosal folds, which involves less than 75% of the circumference. Grade D: One or more mucosal breaks, which involves at least 75% of the circumference.
| percentage of participants | Healing Phase: Vonoprazan 20 mg | Healing Phase: Lansoprazole 30 mg |
|---|---|---|
| Healing Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Had Complete Healing of EE by Week 8 | 91.7 | 72.0 |
A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy.
| percentage of participants | Healing Phase: Vonoprazan 20 mg | Healing Phase: Lansoprazole 30 mg |
|---|---|---|
| Healing Phase: Percentage of Participants Who Had Complete Healing of EE at Week 2 | 74.3 | 68.2 |
A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy. LA Classification of Esophagitis Grading Scale: Grade C: One or more mucosal breaks that are continuous between the tops of 2 or more mucosal folds, which involves less than 75% of the circumference. Grade D: One or more mucosal breaks, which involves at least 75% of the circumference.
| percentage of participants | Maintenance Phase: Vonoprazan 10 mg | Maintenance Phase: Vonoprazan 20 mg | Maintenance Phase: Lansoprazole 15 mg |
|---|---|---|---|
| Maintenance Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Maintained Complete Healing of EE at Week 24 | 74.7 | 77.2 | 61.5 |
A 24-hour heartburn-free day was defined as a day having no heartburn among all diary entries for that day. The percentage of 24-hour heartburn-free days was calculated using all days with at least 1 evening or morning diary entry during the treatment period of this phase.
| percentage of days | Maintenance Phase: Vonoprazan 10 mg | Maintenance Phase: Vonoprazan 20 mg | Maintenance Phase: Lansoprazole 15 mg |
|---|---|---|---|
| Maintenance Phase: Percentage of 24-hour Heartburn-free Days | 80.9 ± 28.59 | 80.6 ± 29.96 | 78.6 ± 27.49 |
Collected over Healing Phase: Day 1 to Week 8; Maintenance Phase: Day 1 to Week 28. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Healing Phase: Vonoprazan 20 mg | 0/514 (0%) | 3/514 (0.6%) | 50/514 (9.7%) |
| Healing Phase: Lansoprazole 30 mg | 0/510 (0%) | 3/510 (0.6%) | 46/510 (9%) |
| Maintenance Phase: Vonoprazan 10 mg | 0/296 (0%) | 10/296 (3.4%) | 72/296 (24.3%) |
| Maintenance Phase: Vonoprazan 20 mg | 2/296 (0.7%) | 14/296 (4.7%) | 81/296 (27.4%) |
| Maintenance Phase: Lansoprazole 15 mg | 0/297 (0%) | 7/297 (2.4%) | 74/297 (24.9%) |
| Event | Healing Phase: Vonoprazan 20 mg | Healing Phase: Lansoprazole 30 mg | Maintenance Phase: Vonoprazan 10 mg | Maintenance Phase: Vonoprazan 20 mg | Maintenance Phase: Lansoprazole 15 mg |
|---|---|---|---|---|---|
| COVID-19Infections and infestations | 1/514 | 0/510 | 1/296 | 2/296 | 0/297 |
| COVID-19 pneumoniaInfections and infestations | 0/514 | 0/510 | 1/296 | 2/296 | 0/297 |
| Oedema peripheralGeneral disorders | 1/514 | 0/510 | 0/296 | 1/296 | 0/297 |
| DiverticulitisInfections and infestations | 0/514 | 0/510 | 1/296 | 0/296 | 0/297 |
| Peritonsillar abscessInfections and infestations | 0/514 | 0/510 | 0/296 | 1/296 | 0/297 |
| SinusitisInfections and infestations | 0/514 | 0/510 | 1/296 | 0/296 | 0/297 |
| Large intestine polypGastrointestinal disorders | 0/514 | 0/510 | 1/296 | 0/296 | 0/297 |
| MelaenaGastrointestinal disorders | 0/514 | 0/510 | 1/296 | 0/296 | 0/297 |
| PancreatitisGastrointestinal disorders | 0/514 | 0/510 | 0/296 | 1/296 | 0/297 |
| PancreatolithiasisGastrointestinal disorders | 0/514 | 0/510 | 0/296 | 1/296 | 0/297 |
| Event | Healing Phase: Vonoprazan 20 mg | Healing Phase: Lansoprazole 30 mg | Maintenance Phase: Vonoprazan 10 mg | Maintenance Phase: Vonoprazan 20 mg | Maintenance Phase: Lansoprazole 15 mg |
|---|---|---|---|---|---|
| COVID-19Infections and infestations | 8/514 | 6/510 | 12/296 | 26/296 | 18/297 |
| DiarrhoeaGastrointestinal disorders | 11/514 | 13/510 | 3/296 | 7/296 | 13/297 |
| DyspepsiaGastrointestinal disorders | 1/514 | 3/510 | 11/296 | 12/296 | 8/297 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 6/514 | 2/510 | 7/296 | 11/296 | 6/297 |
| Abdominal painGastrointestinal disorders | 8/514 | 2/510 | 4/296 | 10/296 | 3/297 |
| Chronic gastritisGastrointestinal disorders | 2/514 | 1/510 | 9/296 | 4/296 | 5/297 |
| HypertensionVascular disorders | 3/514 | 4/510 | 9/296 | 8/296 | 6/297 |
| Urinary tract infectionInfections and infestations | 6/514 | 4/510 | 8/296 | 1/296 | 5/297 |
| Back painMusculoskeletal and connective tissue disorders | 2/514 | 4/510 | 6/296 | 8/296 | 4/297 |
| HeadacheNervous system disorders | 6/514 | 6/510 | 3/296 | 2/296 | 8/297 |
The Randomized Set included all participants randomly assigned to receive study drug regardless of whether or not they received a dose of study drug.
| Age, Categorical(Participants) | Healing Phase: Vonoprazan 20 mg | Healing Phase: Lansoprazole 30 mg | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 421 | 406 | 827 |
| >=65 years | 93 | 107 | 200 |
| Sex: Female, Male(Participants) | Healing Phase: Vonoprazan 20 mg | Healing Phase: Lansoprazole 30 mg | Total |
|---|---|---|---|
| Female | 256 | 289 | 545 |
| Male | 258 | 224 | 482 |
| Ethnicity (NIH/OMB)(Participants) | Healing Phase: Vonoprazan 20 mg | Healing Phase: Lansoprazole 30 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 62 | 59 | 121 |
| Not Hispanic or Latino | 450 | 451 | 901 |
| Unknown or Not Reported | 2 | 3 | 5 |
| Race/Ethnicity, Customized(Participants) | Healing Phase: Vonoprazan 20 mg | Healing Phase: Lansoprazole 30 mg | Total |
|---|---|---|---|
| White | 474 | 458 | 932 |
| Black or African-American | 23 | 41 | 64 |
| Asian | 7 | 6 | 13 |
| American Indian or Alaska Native | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Other | 5 | 5 | 10 |
| Unknown | 1 | 1 | 2 |
| Not Reported | 1 | 0 | 1 |
| Adjudicated Los Angeles (LA) Classification of Esophagitis Grading Scale(Participants) | Healing Phase: Vonoprazan 20 mg | Healing Phase: Lansoprazole 30 mg | Total |
|---|---|---|---|
| Grade A or B | 337 | 336 | 673 |
| Grade C or D | 177 | 174 | 351 |
| Unknown or Not Reported | 0 | 3 | 3 |
Showing the first 100 of 157 sites across 6 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Data from this study will be published; however, it is undecided if patient level data will be made available at this time.
Ran from Oct 2019 to primary completion in Jul 2021, 21 months.
Results were first posted in Jul 2022, 1 year after primary completion.
Of 18 phase 3 interventional studies under Esophagitis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vonoprazan
Phathom Pharmaceuticals, Inc.